NOTE: This video is ONLY available to watch in selected countries and geographies
Jason Levy (Atlanta, USA) and Elizabeth David (Toronto, Canada) talk to Interventional News about the final cohort data from the OPuS One clinical study, the results of which were awarded as Abstract of the Year at the 2021 annual scientific meeting of the Society of Interventional Radiology (20–26 March, online).
The “compelling” data showed “improvement in pain and quality of life” both at three days and sustained out to 12 months following use of the OsteoCool Radiofrequency Ablation System. It also indicated a “lack of delayed skeletal events” such as fractures or neurologic injuries following the procedure. The fact that there were no skeletal-related events is something “you will never see in a radiation oncology trial” adds Levy.
The “significant decrease” in pain scores that were seen within hours and days of the procedure were “pretty startling”, adds David, who also discusses the use of stereotactic body radiation therapy (SBRT), its limitations and where RFA should sit within the standard of care for patients with cancer-related fractures.
Levy goes on to state that the data “really should move the needle more” towards further utilisation of radiofrequency ablation for this patient population.
This video is sponsored by Medtronic.